In Glioblastoma (GBM), Trib2 interacts with MAP kinase kinase kinase 1 (MAP3K1) and enhances resistance to temozolomide (TMZ) chemotherapy and radiotherapy [8]. Here, TRIB2 is linked to glioblastoma.